Scribd Logo
Upload

Welcome to Scribd!

  • 36 views

    Jco.2022.40.16 Suppl.e14002

    Uploaded by

    hamza

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Jco.2022.40.16 Suppl.e14002

    Uploaded by

    hamza
    36 views1 page

    Original Title

    jco.2022.40.16_suppl.e14002 (1)

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    36 views1 page

    Jco.2022.40.16 Suppl.e14002

    Uploaded by

    hamza

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 1

    CENTRAL NERVOUS SYSTEM TUMORS

    e14002 Publication Only


    Outcomes and prognostic factors in patients with HER2-positive metastatic breast
    cancer with brain metastasis.

    Izzet Dogan, Inci Kizildag Yirgin, Selnur Ozkurt, Kamuran Ibõs, Sezai Vatansever, Pinar Saip,
    Adnan Aydiner; Istanbul University Institute of Oncology, Medical Oncology, Istanbul, Turkey; Istan­
    bul University Institute of Oncology, Radiology, Istanbul, Turkey; Istanbul University Institute of Oncol­
    ogy, Radiation Oncology, Istanbul, Turkey

    Background: Breast cancer is the most common malignancy in females. Brain metastasis is a poor prog­
    nostic factor in breast cancer. Brain metastasis can develop in about half of the HER2- positive meta­
    static breast cancer patients. The study was aimed to determine outcomes and prognostic factors in
    HER2 positive metastatic breast cancer patients who had brain metastasis. Methods: We evaluated the
    HER2-positive metastatic breast cancer patients with brain metastasis between 2008 and 2018. Data
    of the patients were recorded retrospectively. Kaplan Meier and Cox regression analysis were used for
    survival analysis and prognostic factors. Results: Eighty-three patients were included in the study. The
    median age was 49 (range, 25-76). Thirty-two (38.6%) patients had de-novo metastatic disease at di­
    agnosis. The most common histopathological type was invasive ductal carcinoma (88.4%). The estro­
    gen receptor and progesterone receptor positivity ratios were 42.2% and 28.9%, respectively. At the
    beginning of brain metastasis, the median number of extra-cranial metastasis was 2 (range, 0-4). The
    most common extra-cranial metastasis sites were bone (63.9%), liver (41%), and lung (34.9%), re­
    spectively. Twenty-eight patients (41.8%) had solitary brain metastasis. The median size of brain me­
    tastasis was 16 mm (range, 5-63) at diagnosis. All patients had treated with trastuzumab-based
    chemotherapy, 29 patients (34.9%) TDM-1, and 73 patients (88%) lapatinib+capesitabine combina­
    tion. Seventeen patients (20.5%) had undergone craniotomy, and 82 patients (98.8%) received brain
    radiotherapy. The patients also received hormonotherapy (41%) and bisphosphonates (56.6%). At a
    median follow-up of 36 months (range 5.9-177.7) from beginning metastasis, the median overall sur­
    vival was 34.9 months (95% CI, range 24.6-45.2). In multivariate analysis, age at diagnosis (p =
    0.005), presence of five and over brain metastasis (p = 0.016), the number of chemotherapy used
    with trastuzumab (p = 0.017), and receiving three different HER2-targetted therapy (p = 0.032) were
    statistically significant for overall survival. However, size of brain metastasis (p = 0.091), lung metas­
    tasis (p = 0.428), liver metastasis (p = 0.338), bone metastasis (p = 0.132), and hormone positivity
    of tumor (p = 0.238) were not. Conclusions: Real-life outcomes of HER2-positive breast cancer pa­
    tients with brain metastases were presented in this study. We showed that age at diagnosis, number of
    brain metastasis, number of chemotherapy received with trastuzumab, and had received three differ­
    ent HER2 targetted therapy was prognostic factors for overall survival. Research Sponsor: None.

    © 2022 by American Society of Clinical Oncology. Visit abstracts.asco.org and search by abstract for disclosure information.
    Downloaded from ascopubs.org by 151.236.166.160 on June 25, 2022 from 151.236.166.160
    Copyright © 2022 American Society of Clinical Oncology. All rights reserved.

    You might also like